A phase 1/2 study on safety of rovalpituzumab tesirine in combination with nivolumab or nivolumab plus ipilimumab in small cell lung cancer-MedSci.cn

A phase 1/2 study on safety of rovalpituzumab tesirine in combination with nivolumab or nivolumab plus ipilimumab in small cell lung cancer

Scripture, C; Selvaggi, G; Lakatos, I; Boynton, K; Lally, S; Han, TH; Peng, SL; Dylla, SJ

ANNALS OF ONCOLOGY, 2017; 28 ( ):

科室
- - 订阅+
  - 更多科室
工具
服务